NCT02285959View on ClinicalTrials.gov

Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Bevacizumab

Trial Locations (1)

Unknown

RECRUITING

Philadelphia

Sponsors
All Listed Sponsors
lead

Global Neurosciences Institute

OTHER